Register for our free email digests:
Value-Added Medicines
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Accord Agrees Leuprolide Deal as Part of Differentiation Strategy
Celltrion’s Subcutaneous Infliximab Shows Promise
Data revealed by Korea’s Celltrion demonstrates that the firm’s subcutaneous infliximab is comparable to the intravenous formulation, with a study showing that auto-injection is a viable administrative method.
TLC Seeks A Second Opinion On Doxolipad
After the CHMP last month refused to recommend granting approval for TLC’s doxorubicin hybrid, the firm has asked the committee within the EMA to revisit its opinion.
Two New Categories Join GGB Awards In 2019
Two new categories – Value Added Medicine Of The Year and Legal Strategy Of The Year – have been added to the Global Generics & Biosimilars Awards in 2019, which will take place on 5 November in Frankfurt, Germany.
European Studies Help Plan A Path Forward For Value Added Medicines
Six value added medicines case studies across six European countries are featured in the latest IQVIA report for Medicines for Europe. Each of them, according to the association’s sector chair Arun Narayan, helps point to a way forward for value added medicines in Europe.
Pfenex One Step Closer To Teriparatide As FDA Accepts NDA
Pfenex maintains it can introduce a follow-on version of Eli Lilly’s Forteo in the fourth quarter of this year, after receiving a target goal date of 7 October 2019 from the FDA.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.